Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Mirum Pharmaceuticals, Inc. (MIRM) reported a Q4 loss of $0.49 per share, which was larger than the Zacks Consensus Estimate of a $0.27 loss. However, the company exceeded revenue expectations.
February 26, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mirum Pharmaceuticals reported a Q4 loss of $0.49 per share, missing the Zacks Consensus Estimate of a $0.27 loss. Despite this, the company exceeded revenue expectations.
The larger-than-expected loss per share is likely to negatively impact the stock price in the short term. However, exceeding revenue expectations may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100